The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma
No effective systemic treatment is available for patients with unresectable, recurrent, or metastatic mucoepidermoid carcinoma (MEC), the most common salivary gland malignancy. MEC is frequently associated with a t(11;19)(q14-21;p12-13) translocation that creates a CRTC1-MAML2 fusion gene. The CRTC1...
Main Authors: | Zirong Chen, Wei Ni, Jian-Liang Li, Shuibin Lin, Xin Zhou, Yuping Sun, Jennifer W. Li, Marino E. Leon, Maria D. Hurtado, Sergei Zolotukhin, Chen Liu, Jianrong Lu, James D. Griffin, Frederic J. Kaye, Lizi Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical investigation
2021-04-01
|
Series: | JCI Insight |
Subjects: | |
Online Access: | https://doi.org/10.1172/jci.insight.139497 |
Similar Items
-
Primary mucoepidermoid carcinoma of the liver with CRTC1-MAML2 fusion: a case report
by: Jiro Watanabe, et al.
Published: (2019-07-01) -
Mucoepidermoid carcinoma of the lacrimal gland in a patient with the CRTC1-MAML2 fusion gene
by: Kensaku Makino, MD, et al.
Published: (2021-12-01) -
Diagnostic Value of MAML2 Rearrangements in Mucoepidermoid Carcinoma
by: Julia C. Thierauf, et al.
Published: (2022-04-01) -
Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma
by: Wei Ni, et al.
Published: (2021-01-01) -
MAML2 negative oncocytic mucoepidermoid carcinoma of submandibular gland
by: Maria Kamal, et al.
Published: (2022-08-01)